Skip to main content
. 2020 Dec 5;12(12):3659. doi: 10.3390/cancers12123659

Table 3.

Retargeting MV receptors by blinding to CD150.

Blinding to Effect Cell Type or Malignancy Model and Type of Virus Delivery to Animals Reference
CD150/SLAM, no natural CD46 Viability of CD150-positive lymphoid cells unaffected; reduced infection of CD46-positive primary normal human cells; tumor stabilized or regressed Breast carcinoma Xenografts;
IT virus delivery		 [63]
Tumor stabilized; animal survival prolonged Pancreatic carcinomas Xenografts;
IT virus delivery		 [64]
Lung carcinoma [65]